Stock Price Movement and Market Context
On 11 December 2025, Sandu Pharmaceuticals' share price touched Rs.36.76, the lowest level recorded in the past year. This price point represents a notable drop from its 52-week high of Rs.62.80. The stock underperformed its sector by 0.44% on the day, reflecting broader pressures within the market. Meanwhile, the Sensex index, after a flat opening with a gain of 65.48 points, declined by 232.83 points to close at 84,223.92, down 0.2%. Despite this, the Sensex remains approximately 2.3% below its 52-week high of 86,159.02 and is trading above its 50-day and 200-day moving averages, indicating a generally bullish trend for the broader market.
Sandu Pharmaceuticals is currently trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This technical positioning suggests sustained downward momentum in the stock price over multiple time horizons.
Financial Performance and Growth Metrics
The company’s financial data over recent years highlights several areas of concern. Over the last five years, Sandu Pharmaceuticals’ net sales have grown at an annual rate of 4.69%, while operating profit has shown a growth rate of 17.92%. These figures indicate modest expansion but fall short of robust growth expectations within the Pharmaceuticals & Biotechnology sector.
In the most recent quarterly results for March 2025, net sales were reported at Rs.14.07 crore, marking the lowest quarterly sales figure in recent periods. This flat sales performance underscores the challenges faced by the company in expanding its revenue base.
Profitability and Return Metrics
The company’s average Return on Equity (ROE) stands at 3.73%, reflecting limited profitability relative to shareholder equity. This level of ROE is considered weak when compared to industry standards, which typically demand higher returns to justify investment.
Despite the subdued ROE, Sandu Pharmaceuticals maintains an attractive valuation with a Price to Book Value ratio of 0.9, suggesting the stock is trading at a discount relative to its book value. This valuation is lower than the average historical valuations of its peers in the sector.
Debt Servicing and Interest Coverage
The company’s ability to service its debt is constrained, with an average EBIT to interest ratio of 1.92. This ratio indicates limited earnings before interest and taxes relative to interest obligations, which may raise concerns about financial flexibility and risk management.
Our latest weekly pick is out! This Large Cap from Steel/Sponge Iron/Pig Iron delivered with target price and complete analysis. See what makes this week's selection special!
- - Latest weekly selection
- - Target price delivered
- - Large Cap special pick
See This Week's Special Pick →
Comparative Performance and Market Position
Sandu Pharmaceuticals has consistently underperformed the benchmark indices over the past three years. The stock has generated a return of -33.47% in the last 12 months, contrasting with the Sensex’s positive return of 3.31% over the same period. Additionally, the stock has lagged behind the BSE500 index in each of the last three annual periods, highlighting persistent challenges in maintaining competitive performance.
Profitability Trends and Valuation Metrics
While the stock price has declined, the company’s profits have shown a rise of 10.9% over the past year. This divergence between profit growth and share price performance is reflected in a PEG ratio of 2.2, indicating the relationship between price, earnings growth, and valuation.
Shareholding Pattern
The majority of Sandu Pharmaceuticals’ shares are held by non-institutional investors, which may influence trading dynamics and liquidity in the stock.
Sandu Pharmaceuticals or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary of Key Indicators
To summarise, Sandu Pharmaceuticals is currently trading at Rs.36.76, its lowest level in the past year, with a 52-week high of Rs.62.80. The stock’s performance over the last year shows a decline of 33.47%, contrasting with the Sensex’s positive 3.31% return. The company’s financial metrics reveal modest sales growth, limited profitability as indicated by a 3.73% ROE, and constrained debt servicing capacity with an EBIT to interest ratio below 2. Valuation metrics suggest the stock is trading at a discount relative to book value and peers’ historical averages.
These factors collectively illustrate the challenges Sandu Pharmaceuticals faces in regaining momentum within the Pharmaceuticals & Biotechnology sector, as reflected in its current share price and market standing.
Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →
